PT  - JOURNAL ARTICLE
AU  - ILHAN-MUTLU, AYSEGÜL
AU  - PREUSSER, MATTHIAS
AU  - SCHOPPMANN, SEBASTIAN F.
AU  - ASARI, REZA
AU  - BA-SSALAMAH, AHMED
AU  - SCHWAMEIS, KATRIN
AU  - PLUSCHNIG, URSULA
AU  - BIRNER, PETER
AU  - PÜSPÖK, ANDREAS
AU  - ZACHERL, JOHANNES
AU  - HEJNA, MICHAEL
TI  - Comparison Between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Adenocarcinoma of the Upper Gastrointestinal Tract
DP  - 2013 Aug 01
TA  - Anticancer Research
PG  - 3455--3459
VI  - 33
IP  - 8
4099  - http://ar.iiarjournals.org/content/33/8/3455.short
4100  - http://ar.iiarjournals.org/content/33/8/3455.full
SO  - Anticancer Res2013 Aug 01; 33
AB  - Background: The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma. In this analysis, we compare DCF and EOX regarding toxicity and efficacy. Patients and Methods: Patients received either intravenous docetaxel at 75 mg/m2, cisplatin at 75 mg/m2, both given on day 1, and 5-fluorouracil at 750 mg/m2, on days 1 to 5, or epirubicin at 50 mg/m2 i.v. on day 1, oxaliplatin at 130 mg/m2 i.v. on day 1 and capecitabine at a twice-daily dose of 1000 mg/m2 p.o. for two weeks; both regimens were repeated every three weeks. Results: Response rates for DCF and EOX were 28% and 10%, time-to-progression was 26 and 20 weeks, and overall survival were 54 and 52 weeks, respectively. Conclusion: We conclude that further investigations within comparative prospective clinical trials of these regimens are warranted.